Adjuvant Endocrine Therapy for Breast Cancer

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Several trials showed that extended adjuvant endocrine therapy beyond 5 years provides additional benefit in terms of reduction of disease recurrence
  • According to ASCO guidelines, all patients with node-positive disease should be offered 10 years of adjuvant ET
  • Guidelines from the European Society for Medical Oncology (ESMO) also note that 10 years of treatment is advantageous. Moreover, women with node-negative breast cancer may be offered extended adjuvant endocrine therapy for up to 10 years, on the basis of considerations of recurrence risk using established prognostic factors
  • Conversely, women with low-risk, node-negative tumors should notroutinely be offered extended therapy because the absolute reduction of recurrence risk is likely to be small in this category of patients
  • The ESMO notes that extended therapy should not be offered to those with a very low risk of relapse
  • Similarly, 5 years of ovarian function suppression with either tamoxifen or an aromatase inhibitor provides an additional benefit for this patient population. However, there is no evidence that continuing ovarian function suppression alone beyond 5 years provides additional benefit

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s